Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Prostate Cancer

Free Subscription Articles published in Oncogene Retrieve available abstracts of 45 articles: HTML format Text format

Single Articles

November 2018
1. PAI VC, Hsu CC, Chan TS, Liao WY, et al
   Correction: ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling.
   Oncogene. 2018 Nov 2. pii: 10.1038/s41388-018-0561.
   PubMed     Text format     Abstract available
   
   
   October 2018
2. SU F, Ahn S, Saha A, DiGiovanni J, et al
   Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance.
   Oncogene. 2018 Oct 25. pii: 10.1038/s41388-018-0558.
   PubMed     Text format     Abstract available
   
   
   
3. PROBERT C, Dottorini T, Speakman A, Hunt S, et al
   Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis.
   Oncogene. 2018 Oct 23. pii: 10.1038/s41388-018-0540.
   PubMed     Text format     Abstract available
   
   
   September 2018
4. PAI VC, Hsu CC, Chan TS, Liao WY, et al
   ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling.
   Oncogene. 2018 Sep 28. pii: 10.1038/s41388-018-0497.
   PubMed     Text format     Abstract available
   
   
   
5. WARREN AY, Massie CE, Watt K, Luko K, et al
   A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.
   Oncogene. 2018 Sep 20. pii: 10.1038/s41388-018-0501.
   PubMed     Text format     Abstract available
   
   
   
6. STYLIANOU N, Lehman ML, Wang C, Fard AT, et al
   A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.
   Oncogene. 2018 Sep 7. pii: 10.1038/s41388-018-0488.
   PubMed     Text format     Abstract available
   
   
   
7. BIRNBAUM MD, Zhao N, Moorthy BT, Patel DM, et al
   Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis.
   Oncogene. 2018 Sep 3. pii: 10.1038/s41388-018-0462.
   PubMed     Text format     Abstract available
   
   
   August 2018
8. LONG MD, Singh PK, Russell JR, Llimos G, et al
   The miR-96 and RARgamma signaling axis governs androgen signaling and prostate cancer progression.
   Oncogene. 2018 Aug 17. pii: 10.1038/s41388-018-0450.
   PubMed     Text format     Abstract available
   
   
   
9. SBRISSA D, Semaan L, Govindarajan B, Li Y, et al
   A novel cross-talk between CXCR4 and PI4KIIIalpha in prostate cancer cells.
   Oncogene. 2018 Aug 15. pii: 10.1038/s41388-018-0448.
   PubMed     Text format     Abstract available
   
   
   July 2018
10. XU Z, Wang Y, Xiao ZG, Zou C, et al
    Nuclear receptor ERRalpha and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer.
    Oncogene. 2018 Jul 24. pii: 10.1038/s41388-018-0409.
    PubMed     Text format     Abstract available
    
    
    June 2018
11. KIM JM, Shin Y, Lee S, Kim MY, et al
    MacroH2A1.2 inhibits prostate cancer-induced osteoclastogenesis through cooperation with HP1alpha and H1.2.
    Oncogene. 2018 Jun 20. pii: 10.1038/s41388-018-0356.
    PubMed     Text format     Abstract available
    
    
    
12. AL SHAREEF Z, Kardooni H, Murillo-Garzon V, Domenici G, et al
    Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1.
    Oncogene. 2018 Jun 1. pii: 10.1038/s41388-018-0294.
    PubMed     Text format     Abstract available
    
    
    May 2018
13. PARK JJ, Park MH, Oh EH, Soung NK, et al
    The p21-activated kinase 4-Slug transcription factor axis promotes epithelial-mesenchymal transition and worsens prognosis in prostate cancer.
    Oncogene. 2018 May 30. pii: 10.1038/s41388-018-0327.
    PubMed     Text format     Abstract available
    
    
    
14. GARG R, Blando JM, Perez CJ, Lal P, et al
    COX-2 mediates pro-tumorigenic effects of PKCepsilon in prostate cancer.
    Oncogene. 2018 May 16. pii: 10.1038/s41388-018-0318.
    PubMed     Text format     Abstract available
    
    
    
15. MADHAV A, Andres A, Duong F, Mishra R, et al
    Antagonizing CD105 enhances radiation sensitivity in prostate cancer.
    Oncogene. 2018 May 2. pii: 10.1038/s41388-018-0278.
    PubMed     Text format     Abstract available
    
    
    March 2018
16. JIA L, Wu D, Wang Y, You W, et al
    Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Oncogene. 2018 Mar 20. pii: 10.1038/s41388-018-0198.
    PubMed     Text format     Abstract available
    
    
    
17. CHENG Y, Gao XH, Li XJ, Cao QH, et al
    Depression promotes prostate cancer invasion and metastasis via a sympathetic-cAMP-FAK signaling pathway.
    Oncogene. 2018 Mar 8. pii: 10.1038/s41388-018-0177.
    PubMed     Text format     Abstract available
    
    
    February 2018
18. LI N, Truong S, Nouri M, Moore J, et al
    Non-canonical activation of hedgehog in prostate cancer cells mediated by the interaction of transcriptionally active androgen receptor proteins with Gli3.
    Oncogene. 2018 Feb 12. pii: 10.1038/s41388-017-0098.
    PubMed     Text format     Abstract available
    
    
    January 2018
19. TAKAYAMA KI, Suzuki T, Tanaka T, Fujimura T, et al
    TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.
    Oncogene. 2018 Jan 30. pii: 10.1038/s41388-017-0095.
    PubMed     Text format     Abstract available
    
    
    
20. METT V, Komarova EA, Greene K, Bespalov I, et al
    Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
    Oncogene. 2018;37:439-449.
    PubMed     Text format     Abstract available
    
    
    
21. STELLOO S, Nevedomskaya E, Kim Y, Hoekman L, et al
    Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.
    Oncogene. 2018;37:313-322.
    PubMed     Text format     Abstract available
    
    
    December 2017
22. MOON SJ, Jeong BC, Kim HJ, Lim JE, et al
    DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.
    Oncogene. 2017 Dec 18. pii: 10.1038/s41388-017-0047.
    PubMed     Text format     Abstract available
    
    
    November 2017
23. GUO Y, Cui J, Ji Z, Cheng C, et al
    miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance.
    Oncogene. 2017;36:6336-6347.
    PubMed     Text format     Abstract available
    
    
    October 2017
24. HAN W, Gao S, Barrett D, Ahmed M, et al
    Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
    Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
    
25. JING Y, Nguyen MM, Wang D, Pascal LE, et al
    DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor.
    Oncogene. 2017 Oct 9. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
    
26. CHANG C, Liu J, He W, Qu M, et al
    A regulatory circuit HP1gamma/miR-451a/c-Myc promotes prostate cancer progression.
    Oncogene. 2017 Oct 2. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
    August 2017
27. GENG C, Kaochar S, Li M, Rajapakshe K, et al
    SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
    Oncogene. 2017;36:4767-4777.
    PubMed     Text format     Abstract available
    
    
    July 2017
28. D'ABRONZO LS, Bose S, Crapuchettes ME, Beggs RE, et al
    The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
    Oncogene. 2017 Jul 24. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
    
29. LI Y, Wang L, Liu J, Zhang P, et al
    O-GlcNAcylation modulates Bmi-1 protein stability and potential oncogenic function in prostate cancer.
    Oncogene. 2017 Jul 17. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
    
30. ASHIKARI D, Takayama K, Tanaka T, Suzuki Y, et al
    Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer.
    Oncogene. 2017 Jul 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
    
31. CHEN WY, Tsai YC, Siu MK, Yeh HL, et al
    Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.
    Oncogene. 2017 Jul 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
    
32. VALENTINO A, Calarco A, Di Salle A, Finicelli M, et al
    Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: molecular basis and pathophysiological consequences.
    Oncogene. 2017 Jul 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
    June 2017
33. CANNISTRACI A, Federici G, Addario A, Di Pace AL, et al
    C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition.
    Oncogene. 2017;36:3718-3728.
    PubMed     Text format     Abstract available
    
    
    
34. TSE BWC, Volpert M, Ratther E, Stylianou N, et al
    Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.
    Oncogene. 2017;36:3417-3427.
    PubMed     Text format     Abstract available
    
    
    
35. PIXBERG CF, Raba K, Muller F, Behrens B, et al
    Analysis of DNA methylation in single circulating tumor cells.
    Oncogene. 2017;36:3223-3231.
    PubMed     Text format     Abstract available
    
    
    
36. PISTORE C, Giannoni E, Colangelo T, Rizzo F, et al
    DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
    May 2017
37. YANG J, Lu C, Wei J, Guo Y, et al
    Inhibition of KPNA4 attenuates prostate cancer metastasis.
    Oncogene. 2017;36:2868-2878.
    PubMed     Text format     Abstract available
    
    
    
38. MCCURDY SR, Pacal M, Ahmad M, Bremner R, et al
    A CDK2 activity signature predicts outcome in CDK2-low cancers.
    Oncogene. 2017;36:2491-2502.
    PubMed     Text format     Abstract available
    
    
    April 2017
39. ZONI E, Chen L, Karkampouna S, Granchi Z, et al
    CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.
    Oncogene. 2017 Apr 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
    
40. DI GIACOMO V, Tian TV, Mas A, Pecoraro M, et al
    DeltaNp63alpha promotes adhesion of metastatic prostate cancer cells to the bone through regulation of CD82.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
    
41. KO CJ, Lan SW, Lu YC, Cheng TS, et al
    Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
    
42. AI J, Pascal LE, Wei L, Zang Y, et al
    EAF2 regulates DNA repair through Ku70/Ku80 in the prostate.
    Oncogene. 2017;36:2054-2065.
    PubMed     Text format     Abstract available
    
    
    March 2017
43. RUAN D, He J, Li CF, Lee HJ, et al
    Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist.
    Oncogene. 2017 Mar 27. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
    
44. KIM J, Jin H, Zhao JC, Yang YA, et al
    FOXA1 inhibits prostate cancer neuroendocrine differentiation.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
    
45. DART AE, Worth DC, Muir G, Chandra A, et al
    The drebrin/EB3 pathway drives invasive activity in prostate cancer.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: